Wolters Kluwer Health Teams up with Amazing Charts/Pri-Med to Enhance Prescription Workflow and Patient Education through EHRs

 

HUDSON, Ohio--Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, is expanding its relationship with Amazing Charts, a division of Pri-Med™, to further both organizations’ missions of enhancing prescription workflow and patient education. The new Pri-Med InLight™ electronic health record (EHR) system employs drug data from Wolters Kluwer Clinical Drug Information solution, Medi-Span®, and makes Wolters Kluwer Integrated Patient Education available to all users.

By 2015, both Amazing Charts EHR and Pri-Med InLight EHR will utilize Wolters Kluwer Integrated Patient Education, an easily accessible and searchable library of more than 6,000 patient-facing educational leaflets, available in up to 19 languages and designed to reinforce providers’ advice and help patients better understand and comply with treatments. Integrated Patient Education provides Pri-Med InLight EHR users with materials on adult and pediatric medications, conditions, procedures, natural products, discharge instructions, and healthy living.Wolters Kluwer Health offerings have long powered decision support functionality in Amazing Charts EHR solutions for outpatient primary care and specialists’ practices. After being acquired by Pri-Med in 2012, Amazing Charts chose Wolters Kluwer Clinical Drug Information solutions to help build Pri-Med InLight, a problem-oriented medical record that emphasizes patient education and engagement. Currently in limited release, Pri-Med InLight debuts to the general marketplace in December 2014.

“When patients understand their treatment plans, they’re more likely to adhere to them, and that can reduce time-consuming and costly readmissions and corrective treatments,” stated Steven Kerscher, Vice President & General Manager, Clinical Drug Information, Wolters Kluwer Health, Clinical Solutions. “Wolters Kluwer Integrated Patient Education is designed to increase health literacy and engagement while improving patient outcomes. It aligns perfectly with the themes that guide Amazing Charts: Providing highly usable solutions for clinicians that help create more time for engaging directly with patients and focusing on connecting patients to their care.”

“Amazing Charts and Pri-Med are focused on helping clinicians make better decisions at the point of care,” said Christine Tremblay, Director of Product Strategy, Amazing Charts. “We support this mission by giving our customers the latest information about medications from Wolters Kluwer, so they can make smart choices for their patients. Education handouts reinforce these choices after the office visit because having more information helps increase patient adherence to prescribed medications. When combined with our patient portal for reminders and follow-up, our clinicians can increase patient contact and influence patient behavior.”

About Wolters Kluwer Health

Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®Lexicomp®Lippincott Williams & WilkinsMedicom®Medi-Span®MedknowOvid®Pharmacy OneSource®ProVation® Medical and UpToDate®.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Follow our official Twitter handle: @WKHealth.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup